Cat. No.: HY-L076

Drug-Induced Liver Injury (DILI) Compound Library

84 Cited Publications

Customer Review

Based on 84 publication(s) in Google Scholar

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (84)
Documentation
Composition

Description & Advantages

• A unique collection of 641 hepatotoxicity causing compounds for high throughput screening (HTS) and high content screening (HCS).

• Including antibiotics, anti-cancer drugs, cardiac medications and anti-inflammatory agent, etc.

• A useful tool for researching drug toxicity and mechanisms of DILI.

• Including several different toxicities: steatosis, mitochondrial toxicity, cholestasis, drug allergy (hypersensitivity), etc.;

• Structurally diverse, bioactive, and cell permeable.

• More detailed compound information with structure, IC₅₀, and brief introduction.

• NMR and HPLC validated ensure high purity.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 641 drug-induced liver injury compounds supplied as pre-dissolved Solutions or Solid

Solution: 629 compounds supplied in 10 mM solution, 8 compounds supplied in 2 mM solution, 4 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice